Press Release (ePRNews.com) - ATLANTA - Apr 11, 2020 - Tissue Regeneration Technologies (TRT) announced today an important addition to our patent family to aid in the fight against the COVID-19. This patent applies the known mechanisms of action of unfocused Shockwaves against this deadly virus. It is documented by prominent researchers and clinicians that;
- Shockwaves activate stem cells
- Modulate inflammation
- Fight infections and viruses
- Mechanically stimulate tissue of different acoustic impedances
- Mechanically dislodge, liquefy and dilute phlegm and mucus
All of these mechanisms may aid in the fight against the Coronavirus. The principles described in the last two bullet points may allow for life-threatening mucous to be expelled more efficiently. As Shockwaves pass through tissue types with differing acoustic properties (lung tissues and thick mucus produced by COVID type viruses), energy is released at the interfaces dislodging the mucus. Additionally, the known anti-inflammatory properties of Shockwaves may modulate the inflammatory overreaction initiated by COVID-19. Finally, the reparative properties of Shockwaves, including the activation of resident stem cells, may aid in the recovery and regeneration of damaged lung tissue.
John Warlick, CEO states, “The most exciting development is that we have treated our first critically affected patients, those already tied to a maxed-out ventilator and ECMO (Extracorporeal Membrane Oxygenation), struggling to survive, having failed all other standard-of-care therapies. These initial treatments are very promising and we will soon be able to release the results. We have been very cautious to develop our unfocused Shockwave (SoftWave®) tools for the treatment of the lungs as there are many misconceptions about the risks associated with Shockwaves and lung tissue developed from the thirty plus years of utilizing high energy, focused Shockwaves to destroy kidney stones. TRT’s unique, patented low energy unfocused Shockwaves do not adversely affect lung tissue as previously feared. This has been demonstrated with small and large animal studies, clinical case reports, and now in the highest-risk patient population. Had the virus affected any other part of the body, we expect to reduce the negative consequences. Hopefully, the disease would not be life-threatening. Because the lungs are the target of the virus, and given our historic misconceptions, we have been very cautious in the use of Shockwaves for lung pathologies. We know unfocused Shockwaves work for these types of indications in other parts in the body, why not the lungs?”
CEO John Warlick further states, “TRT has assembled a team of doctors, engineers, and physicists to support this Herculean effort to eradicate the virus in the lungs. More importantly, TRT will release an open source “white paper” site for others to contribute to this project. This project is too critical to handle on our own. We need to enlist additional experts in this endeavor. We know Shockwaves influence most of the known biologic pathways to disrupt viral replication and aid in the support of the patient’s recovery. We are very confident in the outcome of our fight to destroy the effects of the virus.”
“Ironically, a virus is a very fragile agent. Others seek very elaborate, expensive technologies to fight viruses. Sometimes you just need a sonic hammer. At the most basic level, Shockwaves are just a biologic hammer triggering a basic biological response.”
Please review the attached PDF below for full release.
- (888) 862-6162
Tissue Regeneration Technologies